Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID- 19: a randomized trial

Link to article at PubMed

J Infect Dis. 2023 Jan 31:jiad023. doi: 10.1093/infdis/jiad023. Online ahead of print.


BACKGROUND: COVID-19 convalescent plasma (CCP) reduces hospitalizations among outpatients treated early after symptom onset. It is unknown if CCP reduces time to symptom resolution among outpatients.

METHODS: We evaluated symptom resolution at day 14 by trial arm using an adjusted sub-distribution hazard model, with hospitalization as a competing risk. Additionally, we assessed prevalence of symptom clusters at day 14 between treatments. Clusters were defined based on biologic clustering, impact on ability to work, and an algorithm.

RESULTS: Among 1,070 outpatients followed after transfusion, 381 of 538 (70.8%) receiving CCP and 381 of 532 (71.6%) receiving control plasma were still symptomatic (p = 0.78) at day 14. Associations between CCP and symptom resolution by day 14 were not statistically different from those in controls after adjusting for baseline characteristics (adjusted sub-distribution hazard ratio: 0.99; p = 0.62). The most common cluster consisted of cough, fatigue, shortness of breath, and headache, found in 308 (57.2%) and 325 (61.1%) of CCP and control plasma recipients, respectively (p = 0.16).

CONCLUSIONS: In this trial of outpatients with early COVID-19, CCP was not associated with faster resolution of symptoms compared to control. Overall, there were no differences in the prevalence of each symptom or symptom clusters at day 14 by treatment.

PMID:36722044 | DOI:10.1093/infdis/jiad023

Leave a Reply

Your email address will not be published. Required fields are marked *